Navigation Links
Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
Date:4/18/2008

BEIJING, April 18 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. ("Yongye") (OTC Bulletin Board: GDTN), a leading distributor of plant and animal nutrients headquartered in Beijing, PRC, announced today the completion of a reverse merger and share exchange transaction with the public company formerly known as Golden Tan, Inc. based in Robson, British Columbia, Canada. Simultaneous with the completion of the share exchange transaction, Yongye closed a private placement of its capital stock whereby it received approximately $10.0 million in gross offering proceeds, before payment of commissions and fees. Approximately 6.5 million shares were issued in the private placement at a per share price of $1.54.

The transaction was completed by the exchange of newly issued shares of Yongye for shares held by the shareholders of the holding company controlling the Company's operations in China. Yongye remained the surviving corporation and, as a result of the share exchange, the holding company became a wholly- owned operating subsidiary of Yongye. In connection with the reverse merger, Golden Tan's corporate name was changed to Yongye Biotechnology International, Inc.

In consideration for their shares of Yongye, the shareholders collectively received approximately 84.0% of Yongye's shares after giving effect to the transaction, or 29.2% of Yongye's shares after giving effect to the financing. Furthermore, the officers and directors of Golden Tan were replaced by nominees appointed by Mr. Wu (CEO and Chairman of Yongye), all as more fully disclosed in the Form 8-K being filed with the Securities and Exchange Commission. Golden Tan has ceased all of its existing business operations and will immediately adopt and implement Yongye's business plan.

With headquarters in Beijing and manufacturing plant in Hohhot, Inner Mongolia, Yongye is engaged in the research, development, production and sales of fulvic acid based liquid and powder nutrient compounds used in the agriculture industry. Based on industry research and government testing, Yongye believes its proprietary technology for fulvic acid extraction creates some of the purest and most bioactive fulvic acid and thus some of the most effective plant and animal nutrients on the market in China. Yongye provides our customers with consistently high quality products due to the vertical integration of our manufacturing process from the design of the raw materials production line to the packaging of the finished goods.

Mr. Wu, the Chief Executive Officer and Chairman of Yongye stated, "We would like to thank our placement agent, ROTH Capital Partners, LLC for facilitating our efforts in connection with the financing and going public transaction. We also want to thank all of our new investors who have put their trust in our company and our management team. Our goal is to create value for our shareholders by capitalizing on significant growth opportunities in our market and we will use our access to the U.S. capital markets to help accomplish this."

ROTH Capital Partners, LLC acted as the placement agent in the $10.0 million financing transaction.

The $10.0 million transaction includes a "make good" provision based on the achievement of a net income target for the Company's 2008 fiscal year. Should the Company not achieve $10.3 million in fiscal 2008 net income, the purchasing shareholders in this transaction will receive 2,000,000 shares from the original shareholder for no additional consideration.

FORWARD LOOKING STATEMENTS

Certain of the statements set forth in this press release constitute "Forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward looking statements involve risks and uncertainties, including, but not limited to: statements regarding the Company's products; marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with pharmaceutical companies; and the period of time for which the proceeds of the offering described above will enable Yongye to fund its operations. There can be no assurance that such forward-looking statements will prove to be accurate and Yongye undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Larry Gilmore

Vice President of Corporate Strategy

Tel: +86-8232-8866 x 8880

Fax: +86-10-8231-1797

Email: larry.gilmore@gmail.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
3. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
6. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
7. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
8. Leading Biotechnology Company Grows with StayinFront CRM
9. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, ... Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of ... PathSensors deploys the CANARY® test platform for the detection of harmful pathogens, including ...
(Date:4/27/2016)... , ... April 27, 2016 , ... Global Stem ... GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in Miami. ... where he studied hematopoietic stem cell transplantation for hematologic disorders and the suppression of ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... LOS ANGELES, Calif. (PRWEB) , ... April 27, ... ... Los Angeles office of Lewis Roca Rothgerber Christie LLP as an associate in ... and prosecuting U.S. and international electrical, mechanical and electromechanical patent applications. He has ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):